Literature DB >> 24285373

Microfluidic radiosynthesis and biodistribution of [18 F] 2-(5-fluoro-pentyl)-2-methyl malonic acid.

Gajanan K Dewkar1, Gobalakrishnan Sundaresan, Narottam Lamichhane, Jerry Hirsch, Celina Thadigiri, Thomas Collier, Matthew C T Hartman, Ganesan Vaidyanthan, Jamal Zweit.   

Abstract

Microfluidics technology has emerged as a powerful tool for the radiosynthesis of positron emission tomography (PET) and single-photon emission computed tomography radiolabeled compounds. In this work, we have exploited a continuous flow microfluidic system (Advion, Inc., USA) for the [(18) F]-fluorine radiolabeling of the malonic acid derivative, [(18) F] 2-(5-fluoro-pentyl)-2-methyl malonic acid ([(18) F]-FPMA), also known as [(18) F]-ML-10, a radiotracer proposed as a potential apoptosis PET imaging agent. The radiosynthesis was developed using a new tosylated precursor. Radiofluorination was initially optimized by manual synthesis and served as a basis to optimize reaction parameters for the microfluidic radiosynthesis. Under optimized conditions, radio-thin-layer chromatography analysis showed 79% [(18) F]-fluorine incorporation prior to hydrolysis and purification. Following hydrolysis, the [(18) F]-FPMA was purified by C18 Sep-Pak, and the final product was analyzed by radio-HPLC (high-performance liquid chromatography). This resulted in a decay-corrected 60% radiochemical yield and ≥98% radiochemical purity. Biodistribution data demonstrated rapid blood clearance with less than 2% of intact [(18) F]-FPMA radioactivity remaining in the circulation 60 min post-injection. Most organs showed low accumulation of the radiotracer, and radioactivity was predominately cleared through kidneys (95% in 1 h). Radio-HPLC analysis of plasma and urine samples showed a stable radiotracer at least up to 60 min post-injection.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PET radiochemistry; [18F]-FPMA; [18F]-ML-10; microfluidic technology

Mesh:

Substances:

Year:  2013        PMID: 24285373     DOI: 10.1002/jlcr.3016

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  6 in total

1.  Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates.

Authors:  Frederic Bois; Jean-Dominique Gallezot; Ming-Qiang Zheng; Shu-Fei Lin; Irina Esterlis; Kelly P Cosgrove; Richard E Carson; Yiyun Huang
Journal:  Nucl Med Biol       Date:  2014-08-08       Impact factor: 2.408

2.  In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.

Authors:  Marie Médoc; Martine Dhilly; Lidia Matesic; Jérôme Toutain; Anwen M Krause-Heuer; Jérôme Delamare; Benjamin H Fraser; Omar Touzani; Louisa Barré; Ivan Greguric; Franck Sobrio
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

Review 3.  Biomarkers in preclinical cancer imaging.

Authors:  Monique R Bernsen; Klazina Kooiman; Marcel Segbers; Fijs W B van Leeuwen; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

4.  [18F]-Fluorinated Carboplatin and [111In]-Liposome for Image-Guided Drug Delivery.

Authors:  Narottam Lamichhane; Gajanan K Dewkar; Gobalakrishnan Sundaresan; Rebecca N Mahon; Jamal Zweit
Journal:  Int J Mol Sci       Date:  2017-05-18       Impact factor: 5.923

5.  Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.

Authors:  Vessela Vassileva; Stephen M Stribbling; Chris Barnes; Laurence Carroll; Marta Braga; Joel Abrahams; Kathrin Heinzmann; Caroline Haegeman; Marion MacFarlane; Kathryn L Simpson; Caroline Dive; Jamie Honeychurch; Timothy M Illidge; Eric O Aboagye
Journal:  EJNMMI Res       Date:  2019-02-19       Impact factor: 3.138

Review 6.  Interest and Limits of [18F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy.

Authors:  Elodie Jouberton; Sébastien Schmitt; Aurélie Maisonial-Besset; Emmanuel Chautard; Frédérique Penault-Llorca; Florent Cachin
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.